Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $2.1 million.

  • Anika Therapeutics' Share-based Compensation fell 3862.7% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 3273.66%. This contributed to the annual value of $13.1 million for FY2024, which is 1386.21% down from last year.
  • Per Anika Therapeutics' latest filing, its Share-based Compensation stood at $2.1 million for Q3 2025, which was down 3862.7% from $2.5 million recorded in Q2 2025.
  • Anika Therapeutics' 5-year Share-based Compensation high stood at $4.1 million for Q2 2023, and its period low was $2.1 million during Q3 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $3.4 million (2024), whereas its average is $3.2 million.
  • Per our database at Business Quant, Anika Therapeutics' Share-based Compensation surged by 119130.43% in 2021 and then plummeted by 4089.12% in 2024.
  • Anika Therapeutics' Share-based Compensation (Quarter) stood at $3.2 million in 2021, then grew by 20.44% to $3.8 million in 2022, then grew by 0.05% to $3.8 million in 2023, then tumbled by 40.89% to $2.3 million in 2024, then dropped by 7.63% to $2.1 million in 2025.
  • Its Share-based Compensation was $2.1 million in Q3 2025, compared to $2.5 million in Q2 2025 and $3.0 million in Q1 2025.